Jpmorgan Chase & CO Vigil Neuroscience, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Vigil Neuroscience, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 9,137 shares of VIGL stock, worth $35,817. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,137
Previous 7,116
28.4%
Holding current value
$35,817
Previous $24,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding VIGL
# of Institutions
57Shares Held
26.6MCall Options Held
0Put Options Held
0-
Atlas Venture Life Science Advisors, LLC5.84MShares$22.9 Million3.11% of portfolio
-
Northpond Ventures, LLC4.21MShares$16.5 Million58.42% of portfolio
-
Artal Group S.A. Luxembourg, N41.83MShares$7.17 Million0.46% of portfolio
-
Bvf Inc San Francisco, CA1.81MShares$7.11 Million0.22% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L31.69MShares$6.63 Million0.99% of portfolio
About Vigil Neuroscience, Inc.
- Ticker VIGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,268,600
- Market Cap $111M
- Description
- Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed...